Synthetic Molecular Sensors to Target Latently Infected Cells for HIV Eradication

Information

  • Research Project
  • 8657164
  • ApplicationId
    8657164
  • Core Project Number
    R21AI104282
  • Full Project Number
    7R21AI104282-02
  • Serial Number
    104282
  • FOA Number
    PA-12-270
  • Sub Project Id
  • Project Start Date
    2/1/2013 - 11 years ago
  • Project End Date
    1/31/2015 - 9 years ago
  • Program Officer Name
    LAWRENCE, DIANE M
  • Budget Start Date
    5/1/2013 - 11 years ago
  • Budget End Date
    1/31/2014 - 10 years ago
  • Fiscal Year
    2013
  • Support Year
    02
  • Suffix
  • Award Notice Date
    7/25/2013 - 10 years ago
Organizations

Synthetic Molecular Sensors to Target Latently Infected Cells for HIV Eradication

PROJECT SUMMARY There are no methods currently available for the eradication of the latent reservoir in HIV-infected patients. The long-term goal of the proposed research is to develop a new method based on synthetic molecular sensors that is capable of targeting latently infected cells in HIV-infected patients for destruction. The objective of this particular application is to design constructs known as Synthetic Molecular Sensors for HIV Eradication (SMaSHEd) and determine their ability to eradicate latently infected cells from HIV-infected patients or from in vitro latency models. The central hypothesis is that the promoter regions from host genes and the binding sites for miRNAs whose expression can discriminate latently infected from uninfected cells can be used as sensors in SMaSHEd constructs to specifically express a suicide gene in latently infected cells. The rationale for the proposed research is that new methods for eradicating the latent reservoir are required that specifically target latently infected cells, and do not directly target the variable HIV provirus, require activation of HIV replication, or rely on the host immune system to eradicate activated cells. Guided by strong preliminary data, our hypothesis will be tested by pursuing the following specific aims: (1 & 2) Identify genes and miRNAs whose expression can discriminate latently infected primary CD4 T cells from uninfected cells, and (3) Determine the ability of SMaSHEd constructs to induce cell death in latently infected primary CD4 T cells. The analyses in Aim 1 & 2 will utilize RNA-Seq and smallRNA-Seq to identify the genes and miRNAs, respectively, that are differentially expressed between latently infected and uninfected primary memory CD4 T cells derived from the in vitro model of our collaborator Dr. Vincente Planelles. Our final aim will utilize procedures well established in the realm of synthetic biology to design SMaSHEd constructs containing the promoters and miRNA binding sites of genes (Aim 1) and miRNAs (Aim 2), respectively, that specifically sense the environment in latently infected cells. The ability of these constructs to induce the expression of a suicide gene specifically in latently infected primary CD4 T cells will be assessed following transfection or transduction of mixtures of latently infected and uninfected cells from the in vitro primary CD4 T cell latency model of Dr. Planelles and of Dr. O'Doherty, as well as from HIV-infected patients. The research proposed in this application is innovative, in our opinion, because it will utilize the latest advances in synthetic biology and information gained from next generation sequencing platforms (i.e., RNA-Seq and smallRNA-Seq) to develop a novel method for eradicating latently infected cells. This will be significant because it is the first step in a continuum of research that is expected to lead to the development of a new strategy for the eradication of the latent reservoir in HIV-infected patients. Ultimately, SMaSHEd constructs will be developed for use with appropriate vectors (i.e., adeno-associated virus) for the treatment of HIV-infected patients, where, in contrast to gene therapy, they will only require transient expression to induce the destruction of latently infected cells.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R21
  • Administering IC
    AI
  • Application Type
    7
  • Direct Cost Amount
    132335
  • Indirect Cost Amount
    10587
  • Total Cost
    142922
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:142922\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF SOUTHAMPTON
  • Organization Department
  • Organization DUNS
    225595503
  • Organization City
    SOUTHAMPTON
  • Organization State
  • Organization Country
    UNITED KINGDOM
  • Organization Zip Code
    so17 1bj
  • Organization District
    UNITED KINGDOM